THE EFFECT OF 1000MG DAILY DAFLON TREATMENT ON SAPHENOFEMORAL JUNCTIONAL VALVE COMPETENCE AND REFLUX

Metin Onur Beyaz* and Emin Can Ata

ABSTRACT

Background: It has been shown in studies that there are symptomatic improvements in patients treated with Daflon 500, but studies on its effect on the venous valve are limited to experimental animal studies. In this study, the effect of Daflon 1000mg/day on saphenofemoral junctional (SFJ) valve competence and reflux was investigated. Methods: In this prospective study, 76 patients with insufficiency in the SFJ were treated with 1000mg Daflon daily. SFJ diameter and reflux degree of patients were evaluated and compared with venous Doppler ultrasound before and after 6 months of treatment. Results: The mean age was 46.2±8.6; the female was 48 (63.2%); the mean follow-up was 6.4±2.7 months. Pre- and post-treatment diameters of SFJ were 6.32±1.76 (3.8-10.5) and 5.78±1.61 (3.5-10) mm, respectively. This was not statistically significant (P=0.096). After the treatment, patients with SFJ reflux decreased from 100% to 82.9%, and 17.1% patients recovered from SFJ reflux. This was statistically significant (P=0.016, OR:0.031, 95% CI: 0.002-0.527). Similarly, the number of patients with severe GSV reflux decreased from 40.8% to 21%, this was also statistically significant (P=0.049 and P=0.009). Patients with leg pain decreased from 51.3% to 14.5%, this was statistically severely significant (P<0.001, OR:0.20, 95% CI:0.09-0.44). Patients suffering from ankle swelling and itching were also recovered in a significant number (P=0.0031 and P=0.0029). Conclusion: Six months’ use of Daflon 1000mg/day reduces the reflux of SFJ and GSV, and provides symptomatic relief. In this study model, there is no significant improvement in the SFJ valve diameter.

Keywords: Daflon; reflux; saphenofemoral junction; venous insufficiency.